These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 16834751)

  • 1. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
    Franchini M; Girelli D; Olivieri O; Castaman G; Lippi G; Poli G; Salvagno GL; Tagariello G; Giuffrida A; de Gironcoli M; Morfini M; Berntorp E; Gandini G
    Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thirteen novel mutations in the factor VIII gene in the Nijmegen haemophilia A patient population.
    Boekhorst J; Verbruggen B; Lavergne JM; Costa JM; Schoormans SC; Brons PP; van Kraaij MG; Nováková IR; van Heerde WL
    Br J Haematol; 2005 Oct; 131(1):109-17. PubMed ID: 16173970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
    Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
    J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
    Field JJ; Fenske TS; Blinder MA
    Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of inhibitors in mild/moderate haemophilia A.
    Peerlinck K; Jacquemin M
    Haemophilia; 2006 Dec; 12 Suppl 6():43-7. PubMed ID: 17123393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
    Ter Avest PC; Fischer K; Gouw SC; Van Dijk K; Mauser-Bunschoten EP
    Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of inhibitor development in mild haemophilia A increases with age.
    Mauser-Bunschoten EP; Den Uijl IE; Schutgens RE; Roosendaal G; Fischer K
    Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
    Hay CR; Ludlam CA; Colvin BT; Hill FG; Preston FE; Wasseem N; Bagnall R; Peake IR; Berntorp E; Mauser Bunschoten EP; Fijnvandraat K; Kasper CK; White G; Santagostino E
    Thromb Haemost; 1998 Apr; 79(4):762-6. PubMed ID: 9569189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation.
    Bril WS; MacLean PE; Kaijen PH; van den Brink EN; Lardy NM; Fijnvandraat K; Peters M; Voorberg J
    Haemophilia; 2004 Sep; 10(5):509-14. PubMed ID: 15357778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of factor VIII inhibitors in two patients with moderate haemophilia A.
    Paschal RD; Meeks SL; Neff AT
    Haemophilia; 2013 Jan; 19(1):e55-7. PubMed ID: 23171275
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic risk factors for inhibitors to factors VIII and IX.
    Oldenburg J; Pavlova A
    Haemophilia; 2006 Dec; 12 Suppl 6():15-22. PubMed ID: 17123389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran.
    Haghpanah S; Sahraiian M; Afrasiabi A; Enayati S; Peyvandi F; Karimi M
    Haemophilia; 2011 Sep; 17(5):820-1. PubMed ID: 21371201
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.
    d'Oiron R; Volot F; Reynaud J; Peerlinck K; Goudemand J; Guérois C; Rothschild C; Chambost H; Borel-Derlon A; Roussel-Robert V; Marquès-Verdier A; Lienhart A; Berthier AM; Moreau P; Lambert T;
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S3-9. PubMed ID: 16427382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
    Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
    Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors.
    Majumdar G; Savidge GF
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1031-3. PubMed ID: 8148476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between factor VIII genotype and inhibitor development in hemophilia A.
    Fakharzadeh SS; Kazazian HH
    Semin Thromb Hemost; 2000; 26(2):167-71. PubMed ID: 10919409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment related factors and inhibitor development in children with severe haemophilia A.
    Maclean PS; Richards M; Williams M; Collins P; Liesner R; Keeling DM; Yee T; Will AM; Young D; Chalmers EA;
    Haemophilia; 2011 Mar; 17(2):282-7. PubMed ID: 21070501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
    Thom K; Male C; Falger J; Pabinger I
    Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.